Best et al observed that synergy between KEAP1/NFE2L2 and PI3K pathways promoted lung cancer progression with the altered immune milieu, which supported the compound screening results of inhibitors of PI3K/Akt pathways in this study 13. The gene discussed is KEAP1; the disease is lung cancer.